Pinnacle Medicines (巅峰医药)
OrbiMed-incubated Shanghai–Pennsylvania startup using AI plus physics-based modeling to make oral peptide drugs.
1. Core Product / Service
Pinnacle Medicines (founded 2024) designs oral peptides: peptide drugs meant to be swallowed rather than injected [1][2]. Its platform combines AI with physics-based simulation. The company says potency, stability and gut permeability are optimized together from the first design round, instead of fixing oral bioavailability after a potent binder is found [1][3].
Target selection is deliberately low-risk on biology. Programs go after targets already validated by approved or late-stage injectable biologics, so the main open question is whether an oral peptide can match them [1][2].
Pipeline. All programs are preclinical:
- Lead program in asthma / COPD, planned to enter first-in-human studies by the end of 2026 [1][2].
- Three further programs, in inflammatory bowel disease and atopic dermatitis, planned for the clinic in 2027 [2].
Specific targets and candidate names have not been disclosed.
Wet-lab model: not disclosed. The company had just over 20 employees as of spring 2026, split roughly evenly between Shanghai and Doylestown, Pennsylvania [1]. With a team that small and four programs heading toward the clinic, heavy use of CROs for synthesis, DMPK and IND-enabling work is likely. No lab facility or CRO partner has been named, so this remains an inference.
2. Target Users & Pain Points
- Patients and payers in immunology and respiratory disease. Biologics there work but require injections.
- Large pharma (likely future licensees). Oral peptides could extend franchises built on injectable antibodies. Pinnacle's choice of validated targets suits a licensing or partnering exit, though no deal has been announced.
3. Competitive Landscape
| Player | Positioning | Vs. Pinnacle |
|---|---|---|
| Protagonist Therapeutics (US) | Oral peptides in immunology; oral IL-23R peptide partnered with J&J | The established proof point Pinnacle's thesis rests on, and the incumbent to beat |
| ligit-pharma | Chinese AI peptide-design startup (linear, cyclic, mirror-image peptides) | Earlier stage and platform-plus-partnership. Pinnacle is pure pipeline |
| aipher | Tsinghua AIR spin-out doing small molecules and peptides | Overlaps on peptides; much smaller and earlier |
| schrodinger | Physics-based modeling software plus own pipeline | Pinnacle uses similar physics-plus-AI design, applied to peptides |
| anew-labs | ByteDance spin-out, also pursuing oral IL-17 inhibition | Same "oral replacement for biologics" goal, but with small molecules |
4. Unique Observations
- AI is a tool here, not the business model. Pinnacle was set up by an investor (OrbiMed) around an experienced peptide-chemistry team. It sells nothing to third parties. Among the Chinese AI-native startups founded since 2023, the pure-pipeline companies tend to be investor- or industry-led like this one.
- It is likely to be the first of its cohort in humans. If the end-2026 first-in-human plan holds, Pinnacle will be the earliest of the post-2023 Chinese AI-native drug startups to start a formal clinical study. As of October 2026, none had done so.
- It is a cross-border company by design. It has a Shanghai headquarters, a US site, a US-style board and syndicate (OrbiMed, RA Capital, Foresite), and a CEO with China and US commercial experience. That positions it for global deals, and exposes it to US scrutiny of China-linked biotech.
- Its Chinese name varies by source. Press releases and Chinese healthcare media use 巅峰医药; a law-firm deal note uses 峰肽药业 [5].
5. Financials / Funding
- Incubation / early funding (2024–25): OrbiMed incubated the company and provided its first capital [1][3]. The exact amount is not disclosed; subtracting the Series B from the cumulative total gives about US$45M.
- Series B (26 March 2026): US$89M, oversubscribed [3][4].
- Co-leads: LAV (礼来亚洲基金) and Foresite.
- Participants: Quan Capital, Hankang (汉康), RA Capital, Logos Capital and OrbiMed.
- Total raised: US$134M [1][3].
- Use of funds: taking lead programs to clinical proof of concept [3].
6. People & Relationships
- Co-founder & CSO: 孙承造 (Chengzao Sun; some English reports spell it "Chengzhao"). He previously led peptide drug discovery at Johnson & Johnson, Merck and Amylin [1][2].
- Co-founder & CTO: Sandeep Somani [1].
- CEO (from 1 Jan 2026): Jonathan Wang, former OrbiMed investor and former chief commercial officer of Zai Lab [2][3].
- Incubator / anchor investor: OrbiMed.
- Investors: LAV, Foresite, Quan, Hankang, RA Capital, Logos.
- Peers: ligit-pharma, aipher, anew-labs, aureka-bio.
Sources
- BioBuzz — https://biobuzz.io/news/pinnacle-medicines-89m-raise-signals-a-new-bet-on-oral-peptides-and-a-different-kind-of-biotech-build/
- MedCity News — https://medcitynews.com/2026/04/oral-peptide-startup-pinnacle-medicines-orbimed-asthma-copd-immunology-inflammation/
- Fierce Biotech — https://www.fiercebiotech.com/biotech/orbimed-backed-pinnacle-adds-89m-series-b-power-oral-peptide-pipeline
- VBData — https://www.vbdata.cn/intelDetail/914881
- Law.asia — https://law.asia/zh-hans/?p=680851